Lead Product(s) : KW-6356,Etilevodopa
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kyowa Kirin Announces Discontinuation for Developing KW-6356
Details : KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin, however the company decided to discontinue its phase 2 trial after through evaluation of global regulatory landscape & potential timelines for market entry.
Product Name : KW-6356
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2022
Lead Product(s) : KW-6356,Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Licensing Agreement with Affamed for KDT-3594, a Novel Investigational Drug for Parkinson's Disease
Details : Under this agreement, Kissei grants Affamed the exclusive right for development and commercialization in China, Taiwan, Hong Kong, Macao and six Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines.
Product Name : KDT-3594
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 10, 2020
Lead Product(s) : Soticlestat
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Ovid Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 ELEKTRA Study of Soticlestat Meets Primary Endpoint
Details : Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo in the combined Dravet syndrome and Lennox-Gastaut syndrome study population.
Product Name : TAK-935
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Soticlestat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Ovid Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable